{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:02:24Z","timestamp":1779195744107,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Human papillomavirus infection, the primary cause of cervical cancer (the fourth most common cancer in women), is preventable through prophylactic HPV vaccines. As an alternative to current HPV vaccines, all based on a cocktail of L1 virus-like particles (VLPs) from multiple HPV types, the L2 capsid protein offers cross-protection via a conserved epitope residing at the N-terminus between residues 20\u201338. The Trx-L2\n                    <jats:sub>(20\u221238)<\/jats:sub>\n                    -8mer (Trx-8mer) is an L2-based antigen composed of a polytope of L2\n                    <jats:sub>(20\u221238)<\/jats:sub>\n                    epitopes from eight HPV types inserted into thioredoxin from the hyperthermophilic archaeon\n                    <jats:italic>Pyrococcus furiosus<\/jats:italic>\n                    as a scaffold. We designed multivalent nanoparticle forms of Trx-8mer by using a dodecin protein from\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    (mtDod) assembling into dodecameric nanoparticles as a multimerization platform. Here, we explored two approaches to form dodecameric Trx-8mer nanoparticles: (i) direct fusion of the Trx-8mer to mtDod at the DNA level and (ii) decoration of mtDod nanoparticles after assembly with the Trx-8mer via the protein glue DogTag\/DogCatcher. The reaction between Tag and Catcher results in isopeptide bond formation; thus, the covalent decoration of mtDod particles with the cargo (Trx-8mer) occurs. Despite the formation of nanoparticles by direct genetic fusion, this approach did not offer superior immunogenicity compared with the reference antigen, a heptameric form of the Trx-8mer. However, we showed that the decoration of assembled DogTag-mtDod nanoparticles with the cargo yielded the final antigen with a significant increase in immunogenicity with the induction of high neutralizing and cross-neutralizing antibody titers upon injection to BALB\/c mice. We think that the lower immunogenicity observed with the direct genetic fusion of Trx-8mer to mtDod may be attributed to structural constraints affecting the accessibility of L2 epitopes to B cell receptors. Taken together, our final antigen obtained by decoration of DogTag-mtDod with DogCatcher-Trx-8mer holds potential as a multivalent L2-based antigen candidate for next-generation prophylactic HPV vaccines.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-42678-7","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:19:26Z","timestamp":1773418766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of Mycobacterium tuberculosis dodecin scaffold as a multimerization platform on the immunogenicity of HPV L2 antigens"],"prefix":"10.1038","volume":"16","author":[{"given":"Ecem","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipe Colaco","family":"Mariz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueer","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Nessling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Veitl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiko","family":"Weyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"42678_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(80)92617-3","author":"KH Shah","year":"1980","unstructured":"Shah, K. H., Lewis, M. G., Jenson, A. B., Kurman, R. J. & Lancaster, W. D. Papillomavirus and cervical dysplasia.. Lancet https:\/\/doi.org\/10.1016\/s0140-6736(80)92617-3 (1980).","journal-title":"Lancet"},{"key":"42678_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(82)91273-9","author":"H zur Hausen","year":"1982","unstructured":"zur Hausen, H. Human genital cancer: Synergism between two virus infections or synergism between a virus infection and initiating events.. Lancet https:\/\/doi.org\/10.1016\/s0140-6736(82)91273-9 (1982).","journal-title":"Lancet"},{"key":"42678_CR3","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1073\/pnas.80.12.3812","volume":"80","author":"M D\u00fcrst","year":"1983","unstructured":"D\u00fcrst, M., Gissman, L., Ikenberg, H. & zur Hausen, H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl. Acad. Sci. U. S. A. 80, 3812\u20133815 (1983).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"42678_CR4","unstructured":"A review of human carcinogens. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.. Vol. 100B: 1\u2013441. (2012)."},{"key":"42678_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/rmv.1822","volume":"25","author":"J Doorbar","year":"2015","unstructured":"Doorbar, J., Egawa, N., Griffin, H., Kranjec, C. & Murakami, I. Human papillomavirus molecular biology and disease association. Rev. Med. Virol. 25, 2\u201323. https:\/\/doi.org\/10.1002\/rmv.1822 (2015).","journal-title":"Rev. Med. Virol."},{"key":"42678_CR6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nrc798","volume":"2","author":"H zur Hausen","year":"2002","unstructured":"zur Hausen, H. Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer. 2, 342\u2013350. https:\/\/doi.org\/10.1038\/nrc798 (2002).","journal-title":"Nat. Rev. Cancer."},{"key":"42678_CR7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","volume":"141","author":"C de Martel","year":"2017","unstructured":"de Martel, C., Plummer, M., Vignat, J. & Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer 141, 664\u2013670. https:\/\/doi.org\/10.1002\/ijc.30716 (2017).","journal-title":"Int. J. Cancer"},{"key":"42678_CR8","doi-asserted-by":"publisher","unstructured":"Silva, L. L. D. et al. Malignancy associated with low-risk HPV6 and HPV11: A systematic review and implications for cancer prevention.. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers15164068 (2023).","DOI":"10.3390\/cancers15164068"},{"key":"42678_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/21505594.2014.999570","volume":"6","author":"CU Hubbers","year":"2015","unstructured":"Hubbers, C. U. & Akgul, B. HPV and cancer of the oral cavity. Virulence 6, 244\u2013248. https:\/\/doi.org\/10.1080\/21505594.2014.999570 (2015).","journal-title":"Virulence"},{"key":"42678_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/1096-9071(200007)61:3<289::aid-jmv2>3.0.co;2-z","volume":"61","author":"CA Harwood","year":"2000","unstructured":"Harwood, C. A. et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J. Med. Virol. 61, 289\u2013297. https:\/\/doi.org\/10.1002\/1096-9071(200007)61:3%3C289::aid-jmv2%3E3.0.co;2-z (2000).","journal-title":"J. Med. Virol."},{"key":"42678_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00539-0","volume":"7","author":"FC Mariz","year":"2022","unstructured":"Mariz, F. C. et al. A broadly protective vaccine against cutaneous human papillomaviruses. npj Vaccines 7, 116. https:\/\/doi.org\/10.1038\/s41541-022-00539-0 (2022).","journal-title":"npj Vaccines"},{"key":"42678_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","volume":"146","author":"DM Harper","year":"2017","unstructured":"Harper, D. M. & DeMars, L. R. HPV vaccines - A review of the first decade. Gynecol. Oncol. 146, 196\u2013204. https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.004 (2017).","journal-title":"Gynecol. Oncol."},{"key":"42678_CR13","doi-asserted-by":"publisher","unstructured":"Illah, O. & Olaitan, A. Updates on HPV vaccination.. Diagnostics (Basel) https:\/\/doi.org\/10.3390\/diagnostics13020243 (2023).","DOI":"10.3390\/diagnostics13020243"},{"key":"42678_CR14","unstructured":"World Health Organization Prequalified vaccines [Internet], Accessed on 24.04.25 Available at: <https:\/\/extranet.who.int\/prequal\/vaccines\/prequalified-vaccines"},{"key":"42678_CR15","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.4161\/hv.36121","volume":"10","author":"MH Einstein","year":"2014","unstructured":"Einstein, M. H. et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18\u201345 years: End-of-study analysis of a Phase III randomized trial. Hum. Vaccin. Immunother. 10, 3435\u20133445. https:\/\/doi.org\/10.4161\/hv.36121 (2014).","journal-title":"Hum. Vaccin. Immunother."},{"key":"42678_CR16","doi-asserted-by":"crossref","unstructured":"Restrepo, J. et al. Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety. PEDIATRICS 152 (2023).","DOI":"10.1542\/peds.2022-060993"},{"key":"42678_CR17","doi-asserted-by":"publisher","unstructured":"Chackerian, B. & Peabody, D. S. Factors that govern the induction of long-lived antibody responses.. Viruses https:\/\/doi.org\/10.3390\/v12010074 (2020).","DOI":"10.3390\/v12010074"},{"key":"42678_CR18","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S1470-2045(14)71179-9","volume":"16","author":"JT Schiller","year":"2015","unstructured":"Schiller, J. T. & Muller, M. Next generation prophylactic human papillomavirus vaccines. Lancet. Oncol. 16, e217-225. https:\/\/doi.org\/10.1016\/S1470-2045(14)71179-9 (2015).","journal-title":"Lancet. Oncol."},{"key":"42678_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00779-22","author":"A Godi","year":"2022","unstructured":"Godi, A., Vaghadia, S., Cocuzza, C., Miller, E. & Beddows, S. Contribution of surface-exposed loops on the HPV16 capsid to antigenic domains recognized by vaccine or natural infection induced neutralizing antibodies.. Microbiol. Spectr. https:\/\/doi.org\/10.1128\/spectrum.00779-22 (2022).","journal-title":"Microbiol. Spectr."},{"key":"42678_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.clindermatol.2013.08.008","volume":"32","author":"L Ribeiro-M\u00fcller","year":"2014","unstructured":"Ribeiro-M\u00fcller, L. & M\u00fcller, M. Prophylactic papillomavirus vaccines. Clin. Dermatol. 32, 235\u2013247. https:\/\/doi.org\/10.1016\/j.clindermatol.2013.08.008 (2014).","journal-title":"Clin. Dermatol."},{"key":"42678_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051044","author":"B Huber","year":"2021","unstructured":"Huber, B., Wang, J. W., Roden, R. B. S. & Kirnbauer, R. RG1-VLP and other L2-based, broad-spectrum HPV vaccine candidates. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm10051044 (2021).","journal-title":"J. Clin. Med."},{"key":"42678_CR22","unstructured":"Gavi, T. V. A. Gavi Strategic Goal 4, Market Shaping Roadmap Human Papillomavirus Vaccines. (2023)."},{"key":"42678_CR23","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","volume":"9","author":"D Stelzle","year":"2021","unstructured":"Stelzle, D. et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet. Glob. Health. 9, e161\u2013e169. https:\/\/doi.org\/10.1016\/S2214-109X(20)30459-9 (2021).","journal-title":"Lancet. Glob. Health."},{"key":"42678_CR24","doi-asserted-by":"publisher","first-page":"13927","DOI":"10.1128\/JVI.00936-07","volume":"81","author":"R Gambhira","year":"2007","unstructured":"Gambhira, R. et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J. Virol. 81, 13927\u201313931. https:\/\/doi.org\/10.1128\/JVI.00936-07 (2007).","journal-title":"J. Virol."},{"key":"42678_CR25","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/j.vaccine.2009.01.102","volume":"27","author":"I Rubio","year":"2009","unstructured":"Rubio, I. et al. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20\u201338) peptide displayed on bacterial thioredoxin. Vaccine 27, 1949\u20131956. https:\/\/doi.org\/10.1016\/j.vaccine.2009.01.102 (2009).","journal-title":"Vaccine"},{"key":"42678_CR26","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1073\/pnas.73.10.3671","volume":"73","author":"HM Dintzis","year":"1976","unstructured":"Dintzis, H. M., Dintzis, R. Z. & Vogelstein, B. Molecular determinants of immunogenicity: The immunon model of immune response. Proc. Natl. Acad. Sci. U.S.A. 73, 3671\u20133675 (1976).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"42678_CR27","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","volume":"176","author":"J Marcandalli","year":"2019","unstructured":"Marcandalli, J. et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for Respiratory Syncytial Virus. Cell 176, 1420-1431 e1417. https:\/\/doi.org\/10.1016\/j.cell.2019.01.046 (2019).","journal-title":"Cell"},{"key":"42678_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18177-1","author":"G Spagnoli","year":"2017","unstructured":"Spagnoli, G. et al. Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-017-18177-1 (2017).","journal-title":"Sci. Rep."},{"key":"42678_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01930-17","author":"S Pouyanfard","year":"2018","unstructured":"Pouyanfard, S. et al. Minor capsid protein L2 polytope induces broad protection against oncogenic and mucosal Human Papillomaviruses. J. Virol. https:\/\/doi.org\/10.1128\/JVI.01930-17 (2018).","journal-title":"J. Virol."},{"key":"42678_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69990-0","volume":"10","author":"F Bourdeaux","year":"2020","unstructured":"Bourdeaux, F. et al. Dodecin as carrier protein for immunizations and bioengineering applications. Sci. Rep. 10, 13297. https:\/\/doi.org\/10.1038\/s41598-020-69990-0 (2020).","journal-title":"Sci. Rep."},{"key":"42678_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jsb.2011.04.013","volume":"175","author":"F Liu","year":"2011","unstructured":"Liu, F. et al. Structural and biophysical characterization of Mycobacterium tuberculosis dodecin Rv1498A. J. Struct. Biol. 175, 31\u201338. https:\/\/doi.org\/10.1016\/j.jsb.2011.04.013 (2011).","journal-title":"J. Struct. Biol."},{"key":"42678_CR32","doi-asserted-by":"publisher","unstructured":"Keeble, A. H. et al. DogCatcher allows loop-friendly protein-protein ligation. Cell Chem Biol 29, 339\u2013350 e310, (2022). https:\/\/doi.org\/10.1016\/j.chembiol.2021.07.005","DOI":"10.1016\/j.chembiol.2021.07.005"},{"key":"42678_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008827","volume":"16","author":"X Zhao","year":"2020","unstructured":"Zhao, X. et al. Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine. PLoS Pathog. 16, e1008827. https:\/\/doi.org\/10.1371\/journal.ppat.1008827 (2020).","journal-title":"PLoS Pathog."},{"key":"42678_CR34","doi-asserted-by":"publisher","first-page":"5354","DOI":"10.1039\/d3mh00717k","volume":"10","author":"SK Filippov","year":"2023","unstructured":"Filippov, S. K. et al. Dynamic light scattering and transmission electron microscopy in drug delivery: A roadmap for correct characterization of nanoparticles and interpretation of results. Mater. Horiz. 10, 5354\u20135370. https:\/\/doi.org\/10.1039\/d3mh00717k (2023).","journal-title":"Mater. Horiz."},{"key":"42678_CR35","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/s0969-2126(96)00079-2","volume":"4","author":"A Weichsel","year":"1996","unstructured":"Weichsel, A., Gasdaska, J. R., Powis, G. & Montfort, W. R. Crystal structures of reduced, oxidized, and mutated human thioredoxins: Evidence for a regulatory homodimer. Structure 4, 735\u2013751. https:\/\/doi.org\/10.1016\/s0969-2126(96)00079-2 (1996).","journal-title":"Structure"},{"key":"42678_CR36","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1016\/j.vaccine.2014.03.033","volume":"32","author":"H Seitz","year":"2014","unstructured":"Seitz, H. et al. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses. Vaccine 32, 2610\u20132617. https:\/\/doi.org\/10.1016\/j.vaccine.2014.03.033 (2014).","journal-title":"Vaccine"},{"key":"42678_CR37","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.52687","author":"EH Kim","year":"2020","unstructured":"Kim, E. H. et al. Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway. eLife https:\/\/doi.org\/10.7554\/eLife.52687 (2020).","journal-title":"eLife"},{"key":"42678_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10101683","author":"F Gao","year":"2022","unstructured":"Gao, F. et al. AddaVax-Adjuvanted H5N8 inactivated vaccine induces robust humoral immune response against different clades of H5 viruses. Vaccines (Basel) https:\/\/doi.org\/10.3390\/vaccines10101683 (2022).","journal-title":"Vaccines (Basel)"},{"key":"42678_CR39","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrmicro2872","volume":"10","author":"JT Schiller","year":"2012","unstructured":"Schiller, J. T. & Lowy, D. R. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat. Rev. Microbiol. 10, 681\u2013692. https:\/\/doi.org\/10.1038\/nrmicro2872 (2012).","journal-title":"Nat. Rev. Microbiol."},{"key":"42678_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.612747","author":"J-L Palgen","year":"2021","unstructured":"Palgen, J.-L. et al. Optimize Prime\/Boost vaccine strategies: Trained immunity as a new player in the game. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.612747 (2021).","journal-title":"Front. Immunol."},{"key":"42678_CR41","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.24.581861","author":"S Bhattacharya","year":"2024","unstructured":"Bhattacharya, S. et al. Heterologous Prime-Boost with Immunologically Orthogonal Protein Nanoparticles for Peptide Immunofocusing. bioRxiv https:\/\/doi.org\/10.1101\/2024.02.24.581861 (2024).","journal-title":"bioRxiv"},{"key":"42678_CR42","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1016\/j.vaccine.2007.12.060","volume":"26","author":"S Wang","year":"2008","unstructured":"Wang, S. et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26, 3947\u20133957. https:\/\/doi.org\/10.1016\/j.vaccine.2007.12.060 (2008).","journal-title":"Vaccine"},{"key":"42678_CR43","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","volume":"21","author":"S Lu","year":"2009","unstructured":"Lu, S. Heterologous prime\u2013boost vaccination. Curr. Opin. Immunol. 21, 346\u2013351. https:\/\/doi.org\/10.1016\/j.coi.2009.05.016 (2009).","journal-title":"Curr. Opin. Immunol."},{"key":"42678_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1231274","volume":"14","author":"D Pflumm","year":"2023","unstructured":"Pflumm, D. et al. Heterologous DNA-prime\/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice. Front. Immunol. 14, 1231274. https:\/\/doi.org\/10.3389\/fimmu.2023.1231274 (2023).","journal-title":"Front. Immunol."},{"key":"42678_CR45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/ange.202009663","volume":"133","author":"R Rahikainen","year":"2021","unstructured":"Rahikainen, R. et al. Overcoming symmetry mismatch in vaccine nanoassembly through spontaneous amidation. Angew Chem Weinheim Bergstr Ger 133, 325\u2013334. https:\/\/doi.org\/10.1002\/ange.202009663 (2021).","journal-title":"Angew Chem Weinheim Bergstr Ger"},{"key":"42678_CR46","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.vaccine.2022.11.044","volume":"41","author":"S Joshi","year":"2023","unstructured":"Joshi, S. et al. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine 41, 236\u2013245. https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.044 (2023).","journal-title":"Vaccine"},{"key":"42678_CR47","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4161\/hv.26846","volume":"10","author":"YM Hu","year":"2014","unstructured":"Hu, Y. M. et al. Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: An open-label phase I clinical trial. Hum. Vaccin. Immunother. 10, 469\u2013475. https:\/\/doi.org\/10.4161\/hv.26846 (2014).","journal-title":"Hum. Vaccin. Immunother."},{"key":"42678_CR48","unstructured":"WHO. HPV vaccine introduction, Global HPV programme status data[Internet] Accessed on 18.03.25. Available at: https:\/\/immunizationdata.who.int\/."},{"key":"42678_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/srep04729","volume":"4","author":"E Canali","year":"2014","unstructured":"Canali, E. et al. A high-performance thioredoxin-based scaffold for peptide immunogen construction: Proof-of-concept testing with a human papillomavirus epitope. Sci. Rep. 4, 4729. https:\/\/doi.org\/10.1038\/srep04729 (2014).","journal-title":"Sci. Rep."},{"key":"42678_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41577-024-01073-x","volume":"25","author":"SE Degn","year":"2025","unstructured":"Degn, S. E. & Tolar, P. Towards a unifying model for B-cell receptor triggering. Nat. Rev. Immunol. 25, 77\u201391. https:\/\/doi.org\/10.1038\/s41577-024-01073-x (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"42678_CR51","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1021\/acschembio.5b00239","volume":"10","author":"NR Bennett","year":"2015","unstructured":"Bennett, N. R., Zwick, D. B., Courtney, A. H. & Kiessling, L. L. Multivalent antigens for promoting B and T cell activation. ACS Chem. Biol. 10, 1817\u20131824. https:\/\/doi.org\/10.1021\/acschembio.5b00239 (2015).","journal-title":"ACS Chem. Biol."},{"key":"42678_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2021.104890","volume":"155","author":"R Zhao","year":"2021","unstructured":"Zhao, R. et al. Improvement of the immunogenicity of ESAT-6 via fusion with the dodecameric protein dodecin of Mycobacterium tuberculosis. Microb. Pathog. 155, 104890. https:\/\/doi.org\/10.1016\/j.micpath.2021.104890 (2021).","journal-title":"Microb. Pathog."},{"key":"42678_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00914-z","volume":"9","author":"X Zhao","year":"2024","unstructured":"Zhao, X. et al. A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity. NPJ Vaccines 9, 119. https:\/\/doi.org\/10.1038\/s41541-024-00914-z (2024).","journal-title":"NPJ Vaccines"},{"key":"42678_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.606569","volume":"11","author":"F Yang","year":"2020","unstructured":"Yang, F. et al. Broad neutralization responses against oncogenic human papillomaviruses induced by a minor capsid L2 polytope genetically incorporated into bacterial ferritin nanoparticles. Front. Immunol. 11, 606569. https:\/\/doi.org\/10.3389\/fimmu.2020.606569 (2020).","journal-title":"Front. Immunol."},{"key":"42678_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100780","author":"JC Kraft","year":"2022","unstructured":"Kraft, J. C. et al. Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens. Cell. Rep. Med. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100780 (2022).","journal-title":"Cell. Rep. Med."},{"key":"42678_CR56","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tibtech.2014.08.001","volume":"32","author":"G Veggiani","year":"2014","unstructured":"Veggiani, G., Zakeri, B. & Howarth, M. Superglue from bacteria: Unbreakable bridges for protein nanotechnology. Trends Biotechnol. 32, 506\u2013512. https:\/\/doi.org\/10.1016\/j.tibtech.2014.08.001 (2014).","journal-title":"Trends Biotechnol."},{"key":"42678_CR57","doi-asserted-by":"publisher","unstructured":"Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl. Acad. Sci. 109 https:\/\/doi.org\/10.1073\/pnas.1115485109 (2012).","DOI":"10.1073\/pnas.1115485109"},{"key":"42678_CR58","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1073\/pnas.1519214113","volume":"113","author":"G Veggiani","year":"2016","unstructured":"Veggiani, G. et al. Programmable polyproteams built using twin peptide superglues. Proc. Natl. Acad. Sci. U. S. A. 113, 1202\u20131207. https:\/\/doi.org\/10.1073\/pnas.1519214113 (2016).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"42678_CR59","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.tibs.2010.09.007","volume":"36","author":"HJ Kang","year":"2011","unstructured":"Kang, H. J. & Baker, E. N. Intramolecular isopeptide bonds: Protein crosslinks built for stress?. Trends Biochem. Sci. 36, 229\u2013237. https:\/\/doi.org\/10.1016\/j.tibs.2010.09.007 (2011).","journal-title":"Trends Biochem. Sci."},{"key":"42678_CR60","doi-asserted-by":"publisher","first-page":"E6639","DOI":"10.1073\/pnas.1606050113","volume":"113","author":"HH Tam","year":"2016","unstructured":"Tam, H. H. et al. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc. Natl. Acad. Sci. U. S. A. 113, E6639\u2013E6648. https:\/\/doi.org\/10.1073\/pnas.1606050113 (2016).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"42678_CR61","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.immuni.2023.08.011","volume":"56","author":"S Ols","year":"2023","unstructured":"Ols, S. et al. Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses. Immunity 56, 2425-2441 e2414. https:\/\/doi.org\/10.1016\/j.immuni.2023.08.011 (2023).","journal-title":"Immunity"},{"key":"42678_CR62","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1128\/CVI.00195-13","volume":"20","author":"H Seitz","year":"2013","unstructured":"Seitz, H., Dantheny, T., Burkart, F., Ottonello, S. & Muller, M. Influence of oxidation and multimerization on the immunogenicity of a thioredoxin-L2 prophylactic papillomavirus vaccine. Clin. Vaccine Immunol. 20, 1061\u20131069. https:\/\/doi.org\/10.1128\/CVI.00195-13 (2013).","journal-title":"Clin. Vaccine Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42678-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42678-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42678-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:08:08Z","timestamp":1773724088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42678-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42678"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42678-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were performed and reported in accordance with ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"ARRIVE statement"}}],"article-number":"9086"}}